Preemption Policy Demands More Meetings With, Documentation From FDA
Executive Summary
FDA's assertion of the preemption of physician labeling will likely lead to more discussions between sponsors and the agency regarding the presentation of risk information in labeling, according to Coleen Klasmeier, a former special assistant to the FDA's chief counsel
You may also be interested in...
Off-Label Communication Has Risks Beyond Prosecution, Sheehan Says
Pharmaceutical companies should beware of pitfalls of communicating about off-label uses even when such activities can be defended as free speech, Philadelphia Associate U.S. Attorney Jim Sheehan suggested
Off-Label Communication Has Risks Beyond Prosecution, Sheehan Says
Pharmaceutical companies should beware of pitfalls of communicating about off-label uses even when such activities can be defended as free speech, Philadelphia Associate U.S. Attorney Jim Sheehan suggested
Court Ruling On Preemption Leaves Window Open For False Advertising Suits
FDA's failure to include false advertising claims in its policy on preemption implies that the agency "does not intend its review of promotional materials to preempt false advertising claims," according to a recent federal court decision